NASDAQ:CLDX - Celldex Therapeutics, Inc.
$3.79
 $-0.17
-4.29%
4:00PM EDT
2019-04-18
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CLDX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 96   199. 07   233. 87  
42 stocks rank:  3. 34 K 1. 43 K 1. 06 K
# analyst opinions:  1. 00   14. 48   14. 09  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  7. 71   5. 29   1. 92  
current ratio:  7. 86   5. 64   2. 40  

target price low:  6. 05   84. 50   115. 74  
target price avg:  6. 05   110. 73   137. 39  
target price high:  6. 05   136. 41   157. 80  
1-yr high:  12. 12   114. 11   138. 85  
last close:  3. 79   87. 56   116. 78  
50-day avg:  5. 05   95. 43   123. 53  
200-day avg:  5. 63   94. 13   121. 20  
1-yr low:  3. 30   72. 67   98. 41  
volume:  396. 95 K 2. 43 M 4. 85 M
50-day avg volume:  971. 67 K 2. 72 M 4. 97 M
200-day avg volume:  905. 49 K 2. 90 M 4. 58 M

1-day return:  -4. 29 % -0. 40 % 0. 07 %
this week return:  -12. 87 % -5. 72 % -4. 11 %
12-wk return:  -27. 81 % 1. 78 % -0. 04 %
52-wk return:  -60. 26 % 10. 81 % 14. 09 %

enterprise value (EV):  -35. 43 M 51. 19 B 117. 96 B
market cap:  47. 15 M 43. 00 B 104. 52 B
EBITDA:  -71. 60 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  0. 49   4. 34   13. 27  
enterprise/revenue (EV/R):  -3. 71   68. 16   13. 68  
total revenue:  9. 54 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
debt/equity:  3. 65   46. 86   89. 46  
net income (common):  -151. 18 M 2. 20 B 4. 21 B

shares outstanding:  12. 44 M 570. 91 M 1. 24 B
shares:  12. 39 M 571. 02 M 1. 23 B
shares short:  766. 13 K 9. 93 M 16. 79 M
shares short prior month:  383. 32 K 9. 96 M 16. 58 M
short ratio:  1. 96   5. 31   3. 30  
short % of float:  8. 05 % 5. 81 % 2. 61 %
total cash/share:  7. 56   11. 13   9. 30  
total cash:  94. 02 M 6. 70 B 7. 10 B
free cash flow:  -50. 92 M 3. 58 B 4. 74 B
operating cash flow:  -75. 23 M 4. 14 B 6. 32 B

book value:  10. 38   12. 76   26. 84  
price/book:  0. 37   3. 08   -1. 74  
gross profits:  9. 54 M 8. 03 B 34. 77 B
operating margins:  -790. 56 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -31. 58 % --- ---
1-yr mean volatility:  -0. 24 % 0. 03 % 0. 04 %

1-yr EPS:  -14. 48   2. 39   4. 08  
forward EPS:  -3. 60   3. 97   7. 14  
P/E:  -0. 26   13. 59   22. 83  
forward P/E:  -1. 21   -20. 05   14. 49  
PE/G:  0. 01   -1. 46   1. 68  
growth:  -49. 00 % 126. 81 % 29. 29 %
earnings high:  -1. 14   1. 02   1. 63  
earnings avg:  -1. 14   0. 76   1. 51  
earnings low:  -1. 14   0. 47   1. 39  
revenue high:  1. 23 M 2. 68 B 10. 71 B
revenue avg:  1. 23 M 2. 59 B 10. 49 B
revenue low:  1. 23 M 2. 49 B 10. 25 B
return on assets:  -19. 99 % -2. 80 % 5. 29 %
return on equity:  -83. 89 % -18. 52 % 7. 38 %
revenue growth:  -49. 00 % 92. 55 % 19. 15 %
revenue/share:  0. 91   13. 27   55. 24  

beta (1yr vs S&P500):  1. 64   1. 24   0. 93  
sharpe (1yr):  -0. 65   0. 29   0. 60  

held % insiders:  0. 36 % 6. 38 % 3. 38 %
held % institutions:  28. 29 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CLDX
.        + 0 =             0 :: INITIAL WEIGHT
.   + 45.486 =        45.486 :: spline projection addition
.    x 1.432 =        65.137 :: industry recommendation factor
.    x 2.068 =       134.733 :: symbol recommendation factor
.    x 0.998 =       134.464 :: return on assets factor
.    x 0.992 =       133.336 :: return on equity factor
.    x 0.995 =       132.683 :: revenue growth factor
.    x 2.606 =       345.725 :: current ratio factor
.    x 1.072 =       370.585 :: quick ratio factor
.    x 1.229 =       455.414 :: short ratio factor
.    x 2.004 =       912.491 :: price-to-book factor
.    x 1.038 =       947.343 :: debt-to-equity factor
.    x 1.055 =       999.893 :: EBITDA multiple vs industry factor
.    x 5.615 =      5614.318 :: EBITDA multiple factor
.    x 2.173 =     12200.594 :: P/E weight
.    x 2.209 =     26950.614 :: PE/G factor
.    x 1.527 =     41148.782 :: beta factor
.    x 0.653 =     26867.758 :: sharpe factor
.    x 1.837 =     49344.917 :: target low factor
.    x 1.257 =     62040.503 :: target mean factor
.    x 1.077 =     66829.084 :: target high factor
.    x 1.312 =     87656.261 :: industry 2-weeks return factor
.    x 0.923 =      80941.58 :: "drift" penalty 1 days ago
.    x 0.913 =     73863.892 :: "drift" penalty 2 days ago
.     x 0.92 =      67969.81 :: "drift" penalty 5 days ago
.    x 0.995 =      67648.55 :: overall "drift" factor
.    x 0.998 =     67536.115 :: largest single-day jump factor
.    x 0.075 =      5043.773 :: low price factor
.      x 1.0 =       5042.96 :: factor hist industry gain for week 15
.   cubeRoot =        17.149 :: reduced to standardize
.   - 27.255 =          0.96 :: add/subtract for performance
.                       0.96 :: FINAL WEIGHT for NASDAQ:CLDX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org